7N5H
Cryo-EM structure of broadly neutralizing antibody 2-36 in complex with prefusion SARS-CoV-2 spike glycoprotein
Summary for 7N5H
| Entry DOI | 10.2210/pdb7n5h/pdb |
| EMDB information | 24190 |
| Descriptor | Spike glycoprotein, 2-36 Fab heavy chain, 2-36 Fab light chain, ... (5 entities in total) |
| Functional Keywords | sars-cov-2, viral spike, trimer, glycoprotein, neutralizing antibody fab, viral protein-immune system complex, viral protein/immune system |
| Biological source | Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) More |
| Total number of polymer chains | 9 |
| Total formula weight | 513329.87 |
| Authors | Casner, R.G.,Cerutti, G.,Shapiro, L. (deposition date: 2021-06-05, release date: 2021-11-03, Last modification date: 2024-10-16) |
| Primary citation | Wang, P.,Casner, R.G.,Nair, M.S.,Yu, J.,Guo, Y.,Wang, M.,Chan, J.F.,Cerutti, G.,Iketani, S.,Liu, L.,Sheng, Z.,Chen, Z.,Yuen, K.Y.,Kwong, P.D.,Huang, Y.,Shapiro, L.,Ho, D.D. A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses. Emerg Microbes Infect, 11:147-157, 2022 Cited by PubMed Abstract: The repeated emergence of highly pathogenic human coronaviruses as well as their evolving variants highlight the need to develop potent and broad-spectrum antiviral therapeutics and vaccines. By screening monoclonal antibodies (mAbs) isolated from COVID-19-convalescent patients, we found one mAb, 2-36, with cross-neutralizing activity against SARS-CoV. We solved the cryo-EM structure of 2-36 in complex with SARS-CoV-2 or SARS-CoV spike, revealing a highly conserved epitope in the receptor-binding domain (RBD). Antibody 2-36 neutralized not only all current circulating SARS-CoV-2 variants and SARS-COV, but also a panel of bat and pangolin sarbecoviruses that can use human angiotensin-converting enzyme 2 (ACE2) as a receptor. We selected 2-36-escape viruses and confirmed that K378 T in SARS-CoV-2 RBD led to viral resistance. Taken together, 2-36 represents a strategic reserve drug candidate for the prevention and treatment of possible diseases caused by pre-emergent SARS-related coronaviruses. Its epitope defines a promising target for the development of a pan-sarbecovirus vaccine. PubMed: 34836485DOI: 10.1080/22221751.2021.2011623 PDB entries with the same primary citation |
| Experimental method | ELECTRON MICROSCOPY (3.24 Å) |
Structure validation
Download full validation report
